October 7, 2021 (Investorideas.com Newswire) Concurrently, demand is rising for Reliq Well being’s iUGO Care software program as digital healthcare supply will increase through the COVID-19 pandemic.
COVID-19 continues to rage via the U.S., with a present dying price
of greater than 705,000 People. At present, a time when beds in
intensive care models are desperately wanted for SARS-CoV-2 sufferers, Reliq Health Technologies Inc.’s (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) iUGO Care platform helps hold sufferers out of U.S. hospital emergency rooms. On the similar time, healthcare adjustments ensuing from the pandemic are serving to Reliq develop its buyer base.
The telemedicine know-how firm’s iUGO Care platform provides healthcare suppliers entry to real-time distant affected person monitoring knowledge. This permits physicians and their groups to intervene in a well timed style when issues come up, thereby stopping sufferers from visiting the emergency room and/or being hospitalized.
Actually, the platform has been proven to drastically cut back persistent illness sufferers’ danger of hospitalization as a result of issues of their situations. IUGO Care encompasses three modules: Distant Affected person Monitoring, Continual Care Administration, and Behavioral Well being Integration.
The strain of COVID-19, and now its variants, on hospitals has led to payors all through the U.S. increasing reimbursement for distant affected person monitoring and has led to growing numbers of healthcare suppliers delivering care nearly to their sufferers, significantly these with persistent illnesses.
One main purpose of those two shifts is to lower sufferers’ want for and use of emergency room and intensive care unit assets so they continue to be obtainable to COVID-19 sufferers.
Because of the reimbursement development, Texas Medicaid, earlier this 12 months, expanded the variety of persistent situations coated beneath reimbursed distant affected person monitoring providers. This went into impact Sept. 1, 2021.
Earlier than that date, the payor solely reimbursed medical suppliers for distant monitoring of sufferers with diabetes and/or hypertension. Nonetheless now, with the protection enlargement, eligible medical situations additionally embrace congestive coronary heart failure; end-stage illness of the guts, liver, kidney, lung or pancreas; organ transplant; and situations requiring mechanical air flow. Now, Texas Medicaid reimbursement on this regard is extra like Medicare’s, which encompasses much more qualifying situations.
The expanded Texas Medicaid protection is benefitting Reliq Well being in that it simply garnered three extra iUGO Care purchasers within the state, major care medical practices, a news release famous. These teams’ cumulative affected person inhabitants is about 1,500, from which Reliq expects to generate $60 per individual per thirty days. The corporate goals to get all of those sufferers added to the platform this quarter.
1) Doresa Banning compiled this text for Streetwise Studies LLC and offers providers to Streetwise Studies as an unbiased contractor. She or members of her family personal securities of the next corporations talked about within the article: None. She or members of her family are paid by the next corporations talked about on this article: None.
2) The next corporations talked about on this article are billboard sponsors of Streetwise Studies: Reliq Well being Applied sciences Inc. Click on here for vital disclosures about sponsor charges.
3) Feedback and opinions expressed are these of the particular specialists and never of Streetwise Studies or its officers. The data supplied above is for informational functions solely and isn’t a suggestion to purchase or promote any safety.
4) The article doesn’t represent funding recommendation. Every reader is inspired to seek the advice of along with his or her particular person monetary skilled and any motion a reader takes because of info introduced right here is his or her personal accountability. By opening this web page, every reader accepts and agrees to Streetwise Studies’ phrases of use and full authorized disclaimer. This text isn’t a solicitation for funding. Streetwise Studies doesn’t render normal or particular funding recommendation and the knowledge on Streetwise Studies shouldn’t be thought-about a suggestion to purchase or promote any safety. Streetwise Studies doesn’t endorse or suggest the enterprise, merchandise, providers or securities of any firm talked about on Streetwise Studies.
5) Once in a while, Streetwise Studies LLC and its administrators, officers, workers or members of their households, in addition to individuals interviewed for articles and interviews on the positioning, could have an extended or brief place in securities talked about. Administrators, officers, workers or members of their rapid households are prohibited from making purchases and/or gross sales of these securities within the open market or in any other case from the time of the choice to publish an article till three enterprise days after the publication of the article. The foregoing prohibition doesn’t apply to articles that in substance solely restate beforehand printed firm releases. As of the date of this text, officers and/or workers of Streetwise Studies LLC (together with members of their family) personal securities of Reliq Well being Applied sciences Inc., an organization talked about on this article.
6) This text doesn’t represent medical recommendation. Officers, workers and contributors to Streetwise Studies should not licensed medical professionals. Readers ought to all the time contact their healthcare professionals for medical recommendation.
This information is printed on the Investorideas.com Newswire – a worldwide digital information supply for buyers and enterprise leaders
Disclaimer/Disclosure: Investorideas.com is a digital writer of third celebration sourced information, articles and fairness analysis in addition to creates authentic content material, together with video, interviews and articles. Authentic content material created by investorideas is protected by copyright legal guidelines apart from syndication rights. Our website doesn’t make suggestions for purchases or sale of shares, providers or merchandise. Nothing on our websites needs to be construed as a suggestion or solicitation to purchase or promote merchandise or securities. All investing includes danger and attainable losses. This website is at the moment compensated for information publication and distribution, social media and advertising and marketing, content material creation and extra. Disclosure is posted for every compensated information launch, content material printed /created if required however in any other case the information was not compensated for and was printed for the only curiosity of our readers and followers. Contact administration and IR of every firm instantly concerning particular questions.
Extra disclaimer data: https://www.investorideas.com/About/Disclaimer.asp Study extra about publishing your information launch and our different information providers on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
World buyers should adhere to rules of every nation. Please learn Investorideas.com privateness coverage: https://www.investorideas.com/About/Private_Policy.asp